免疫检查点抑制剂在表皮生长因子受体基因突变型晚期非小细胞癌中的应用现状与未来  

Current status and future directions of immune checkpoint inhibitors in EGFR-mutated advanced nonsmall cell lung cancer

作　　者：李星原 虞永峰 穆书雅 陆舜[1] LI Xingyuan;YU Yongfeng;MU Shuya;LU Shun(Department of Medical Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China)

机构地区：[1]上海交通大学医学院附属胸科医院肿瘤内科,上海200030

出　　处：《肿瘤》2024年第6期555-565,共11页Tumor

基　　金：国家自然科学基金面上项目(82172633);北京市希思科-恒瑞肿瘤研究基金面上项目(Y-HR2020MS-0982)

摘　　要：表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)中常见的致癌驱动突变。针对此类基因突变型患者,一线治疗的首选方案是采用EGFR-酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)进行靶向治疗,但是在治疗过程中不可避免地会出现药物抵抗和疾病进展的问题。EGFR-TKI靶向治疗失败后一般采用标准的含铂双药物化疗方案,但其治疗效果有限,亟需探索更为有效的治疗策略。近年来,许多研究已经证实免疫治疗在NSCLC患者中的有效性。然而,对于EGFR突变型晚期NSCLC患者而言,单药免疫治疗的疗效并不理想,因此免疫联合治疗的方案正受到越来越多的关注。Epidermal growth factor receptor(EGFR)gene mutation is a common oncogenic driver mutation in non-small cell lung cancer(NSCLC).For patients with this gene mutation,the preferred firstline treatment is targeted therapy with an EGFR tyrosine kinase inhibitor,but the issues of drug resistance and disease progression will inevitably arise during the treatment.Standard platinumbased doublet chemotherapy regiment after failure of EGFR-TKIs has limited benefit,and more effective treatment strategies urgently need to be developed.In recent years,many studies have confirmed the efficacy of immunotherapy in NSCLC patients.Nevertheless,for advanced NSCLC patients with EGFR gene mutations,the efficacy of immunotherapy monotherapy is not satisfactory,thus immunotherapy-based combination therapy is receiving increasing attention.

关 键 词：非小细胞肺癌 表皮生长因子受体 免疫治疗 耐药 

分 类 号：R734.2[医药卫生—肿瘤]